prostate cancer

[Journal of Gene Medicine] PlncRNA-1 inhibits ZEB1 and activated MAPK1 signaling through upregulating EZH2, thereby enhancing the proliferation and differentiation of hair follicle stem cells and wound healing.

[Accutar Biotechnology, Inc.] Accutar Biotechnology, Inc. announced that the US FDA has cleared the company’s investigational new drug application (IND) for AC0176 for the treatment of patients with metastatic CRPC.

[Journal of Cancer] Researchers investigated the high level of EIF3J‐AS1 in prostate cancer (PCa) tissues and cells, and used functional assays to show that knocking down EIF3J‐AS1 inhibited PCa cell proliferation and metastatic ability.

[Bioengineered] Scientists constructed prostate-specific membrane antigen (PSMA)-knockdown LNCaP and 22rv1 cell lines and performed metabonomic and transcriptomic analyses to determine the effects of PSMA on prostate cancer metabolism and transcription.

[Radiation Research] Investigators demonstrated that STAT3 blockade with a STAT3 inhibitor or siRNA increased the radiosensitivity of prostate cancer (PCa) cells and that radiation together with STAT3 blockade induced more apoptosis and double-strand breaks than radiation alone in LNCaP cells.

[International Journal of Cancer] Investigators showed that ablation of type I fibroblast growth factor receptor (FGFR1) in DU145 human prostate cancer cells changed the cell metabolite profile. Among the changes, the choline metabolism profile was the most significantly altered by FGFR1 ablation.